ArticleHaematologica2018
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Incidence of arterial and venous thromboembolism in cancer patients- insights from more than 5,000,000 patients.Journal of thrombosis and thrombolysis · 2025Pooled it
- Trial
- Research advances on platelet glycoprotein VI in ischemic stroke.Thrombosis journal · 2026Review
- Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.Blood advances · 2026Article
- Haemostasis and the Need for Antithrombotics: An Introduction.Handbook of experimental pharmacology · 2026Review
- Clinical Characteristics and Prognosis of Thromboembolism in Elderly Patients With Stage IV Lung Cancer.Geriatrics & gerontology international · 2026Article
- αIIbβ3-dependent platelet procoagulant activity promotes pulmonary arterial thrombosis triggered by circulating tissue factor.Thrombosis research · 2025Article
- Cancer-Associated Thrombosis (CAT); mechanisms and treatment options.Thrombosis journal · 2025Review
- Analysis of the effect of arterial embolization combined with external fixation in the treatment of unstable pelvic fracture with hemorrhagic shock.Scientific reports · 2025Article
- Development and validation of a risk assessment tool for ischemic stroke in cancer patients.Scientific reports · 2025Article
- Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer.Cancer medicine · 2025Article
- Article
- Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.EClinicalMedicine · 2025Article
- A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database.Scientific reports · 2025Article
- Clonal hematopoiesis in patients with cancer and its association with risk of thrombosis and prognosis of disease.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders.Hematology reports · 2025Review
- Development of a Predictive Model of Occult Cancer After a Venous Thromboembolism Event Using Machine Learning: The CLOVER Study.Medicina (Kaunas, Lithuania) · 2024Article
- Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors.Discover oncology · 2024Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and investigate its potential impact on mortality. Patients with newly-diagnosed cancer or progression of disease after remission were included in a prospective observational cohort study and followed for two years. Between October 2003 and October 2013, 1880 patients (54.3% male; median age 61 years) were included. During a median follow up of 723 days, 48 (2.6%) patients developed arterial thromboembolism [20 (41.7%) myocardial infarction, 16 (33.3%) stroke and 12 (25.0%) peripheral arterial events], 157 (8.4%) developed venous thromboembolism, and 754 (40.1%) patients died. The cumulative 3-, 6-, 12-, and 24-month risks of arterial thromboembolism were 0.9%, 1.1%, 1.7%, and 2.6%, respectively. Male sex (subdistribution hazard ratio=2.9, 95%CI: 1.5-5.6;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.